New therapeutic advances in the management of progressive thyroid cancer.
The spectrum of thyroid cancers ranges from one of the most indolent to one of the most aggressive solid tumors identified. Conventional therapies for thyroid cancers are based on the histologic type of thyroid cancers such as papillary or follicular thyroid cancer (differentiated thyroid cancer (DTC)), medullary thyroid cancer (MTC), or anaplastic thyroid cancer (ATC). While surgery is one of the key treatments for all such types of thyroid cancers, additional therapies vary. Effective targeted therapy for DTC is a decades-old practice with systemic therapies of thyroid stimulating hormone suppression and radioactive iodine therapy. However, for the iodine-refractory DTC, MTC, and ATC there is no effective systemic standard of care treatment. Recent advances in understanding pathogenesis of DTC and development of molecular targeted therapy have dramatically transformed the field of clinical research in thyroid cancer. Over the last five years, incredible progress has been made and phases I-III clinical trials have been conducted in various types of thyroid cancers with some remarkable results that has made an impact on lives of patients with thyroid cancer. Such history-making events have boosted enthusiasm and interest among researchers, clinicians, patients, and sponsors and we anticipate ongoing efforts to develop more effective and safe therapies for thyroid cancer.
Woyach
Jennifer A
JA
Department of Internal Medicine, The Ohio State University, A438 Starling-Loving Hall, 320 West 10th Avenue, Columbus, Ohio 43210, USA.
Shah
Manisha H
MH
D000818:Animals; D024221:Antineoplastic Protocols; D002277:Carcinoma / Q000209:etiology / Q000628:therapy*; D018276:Carcinoma, Medullary / Q000209:etiology / Q000628:therapy; D002291:Carcinoma, Papillary / Q000209:etiology / Q000628:therapy; D002986:Clinical Trials as Topic / Q000379:methods / Q000639:trends; D018450:Disease Progression; D004353:Drug Evaluation, Preclinical / Q000379:methods / Q000639:trends; D006801:Humans; D008954:Models, Biological; D013964:Thyroid Neoplasms / Q000209:etiology / Q000628:therapy*